0.75

3.15% +0.0229

After Hours: .775 0.025 +3.33%

Lipella Pharmaceuticals Inc (LIPO)

Overview News Price History Financials Discussions Forecast

Lipella Pharmaceuticals Inc stock is currently priced at $0.75, with a 24-hour trading volume of 47,799. It has seen a +3.15% increased in the last 24 hours and a +7.14% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.7247 pivot point. If it approaches the $0.7603 resistance level, significant changes may occur.

Previous Close:

$0.7271

Open:

$0.722

24h Volume:

47,799

Market Cap:

$5.28M

Revenue:

Net Income/Loss:

$-4.62M

P/E Ratio:

-1.1581

EPS:

-0.6476

Net Cash Flow:

$-3.15M

1W Performance:

+5.86%

1M Performance:

+7.14%

6M Performance:

-34.78%

1Y Performance:

-60.53%

1D Range:

$0.722

$0.76

52W Range:

$0.64

$2.71

Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile

Name

Lipella Pharmaceuticals Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

412-894-1853

Address

7800 Susquehanna St., Suite 505, Pittsburgh

Employee

Twitter

Next Earnings Date

Latest SEC Filings

LIPO's Discussions on Twitter

Lipella Pharmaceuticals Inc Stock (LIPO) Latest News

Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise

GlobeNewswire Inc.

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

GlobeNewswire Inc.

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

GlobeNewswire Inc.

Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline

GlobeNewswire Inc.

Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

GlobeNewswire Inc.

Lipella Pharmaceuticals Inc Stock (LIPO) Financials Data

Lipella Pharmaceuticals Inc (LIPO) Net Income 2024

LIPO net income (TTM) was -$4.62 million for the quarter ending December 31, 2023, a -77.81% decrease year-over-year.

Lipella Pharmaceuticals Inc (LIPO) Cash Flow 2024

LIPO recorded a free cash flow (TTM) of -$3.15 million for the quarter ending December 31, 2023, a -72.03% decrease year-over-year.

Lipella Pharmaceuticals Inc (LIPO) Earnings per Share 2024

LIPO earnings per share (TTM) was -$0.78 for the quarter ending December 31, 2023, a -72.49% decline year-over-year.

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.